E
Elvira Umyarova
Researcher at University of Vermont
Publications - 37
Citations - 554
Elvira Umyarova is an academic researcher from University of Vermont. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 24 publications receiving 303 citations. Previous affiliations of Elvira Umyarova include Medical University of South Carolina & University of Vermont Medical Center.
Papers
More filters
Journal ArticleDOI
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H. Gandhi,Robert F. Cornell,Arjun Lakshman,Zhubin Gahvari,Elizabeth McGehee,Megan Jagosky,Ridhi Gupta,William Varnado,Mark A. Fiala,Saurabh Chhabra,Ehsan Malek,Joshua Mansour,Barry Paul,Alyssa Barnstead,Saranya Kodali,Amarendra K. Neppalli,Michaela Liedtke,Swapna Narayana,Kelly N. Godby,Yubin Kang,Ankit Kansagra,Elvira Umyarova,Emma C. Scott,Parameswaran Hari,Ravi Vij,Saad Z. Usmani,Natalie S. Callander,Shaji Kumar,Luciano J. Costa +28 more
TL;DR: Patients with MM refractory to CD38 MoAB have poor prognosis and this study provides benchmark for new therapies to be tested in this population.
Journal ArticleDOI
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
James N. Gerson,Elizabeth Handorf,Diego Villa,Alina S. Gerrie,Parv Chapani,Shaoying Li,L. Jeffrey Medeiros,Michael I. Wang,Jonathon B. Cohen,Oscar Calzada,Michael C. Churnetski,Brian T. Hill,Yazeed Sawalha,Francisco J. Hernandez-Ilizaliturri,Shalin Kothari,Julie M. Vose,Martin Bast,Timothy S. Fenske,Swapna Narayana Rao Gari,Kami J. Maddocks,David A. Bond,Veronika Bachanova,Bhaskar Kolla,Julio C. Chavez,Bijal D. Shah,Frederick Lansigan,Timothy F. Burns,Alexandra M. Donovan,Nina D. Wagner-Johnston,Marcus Messmer,Amitkumar Mehta,Jennifer Kelly Anderson,Nishitha Reddy,Alexandra E. Kovach,Daniel J. Landsburg,Martha Glenn,David J. Inwards,Reem Karmali,Jason B. Kaplan,Paolo Caimi,Saurabh Rajguru,Andrew M. Evens,Andreas K. Klein,Elvira Umyarova,Bhargavi Pulluri,Jennifer E Amengual,Jennifer K. Lue,Catherine Diefenbach,Richard I. Fisher,Stefan K. Barta +49 more
TL;DR: In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis, and it is suggested that in younger, fit patients,AHCT consolidation may improve PFS.
Journal ArticleDOI
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
Luciano J. Costa,Kami J. Maddocks,Narendranath Epperla,Nishitha Reddy,Reem Karmali,Elvira Umyarova,Veronika Bachanova,Cristiana A Costa,Martha Glenn,Julio C. Chavez,Oscar Calzada,Frederick Lansigan,Hossain Nasheed,Stefan K. Barta,Zheng Zhou,Michael Jaglal,Saurabh Chhabra,Francisco J. Hernandez-Ilizaliturri,Ana C. Xavier,Amitkumar Mehta,Deniz Peker,Andreas Forero-Torres,Zeina Al-Mansour,Andrew M. Evens,Jonathon B. Cohen,Christopher R. Flowers,Timothy S. Fenske,Mehdi Hamadani +27 more
TL;DR: Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.
Journal ArticleDOI
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Robert F. Cornell,Parameswaran Hari,Shijie Tang,Noa Biran,Natalie S. Callander,Ajai Chari,Saurabh Chhabra,Mark A. Fiala,Zhubin Gahvari,Ujjawal H. Gandhi,Kelly N. Godby,Ridhi Gupta,Sundar Jagannath,Megan Jagosky,Yubin Kang,Ankit Kansagra,Michael Kauffman,Saranya Kodali,Shaji Kumar,Arjun Lakshman,Michaela Liedtke,Sagar Lonial,Xiwen Ma,Ehsan Malek,Joshua Mansour,Joshua Mansour,Elizabeth McGehee,Amarendra K. Neppalli,Barry Paul,Paul G. Richardson,Emma C. Scott,Sharon Shacham,Jatin P. Shah,David S. Siegel,Elvira Umyarova,Saad Z. Usmani,William Varnado,Ravi Vij,Luciano J. Costa +38 more
TL;DR: A ten year review of the sickle cell program in Muhimbili National Hospital, Tanzania and the World Health Organization and Health Action International's Measuring Medicine Price, Availability, Affordability and Price Component.
Journal ArticleDOI
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Narendranath Epperla,Kami J. Maddocks,Mohammed Salhab,Julio C. Chavez,Nishitha Reddy,Reem Karmali,Elvira Umyarova,Veronika Bachanova,Cristiana A Costa,Martha Glenn,Oscar Calzada,Ana C. Xavier,Zheng Zhou,Nasheed Hossain,Francisco J. Hernandez-Ilizaliturri,Zeina Al-Mansour,Stefan K. Barta,Saurabh Chhabra,Frederick Lansigan,Amitkumar Mehta,Michael Jaglal,Andrew J. Evans,Christopher R. Flowers,Jonathon B. Cohen,Timothy S. Fenske,Mehdi Hamadani,Luciano J. Costa +26 more
TL;DR: The impact of MYC proto‐oncogene, basic helix‐loop‐helix (MYC) translocations (with or without additional rearrangements involving the B‐cell lymphoma 2 [BCL2] or BCL6 genes) on the response to salvage therapy and survival in patients with diffuse large B‐ cell lymphoma (DLBCL) who experience primary treatment failure is not well defined.